INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces the submission of a manuscript detailing the results of its Phase 2 MINDFuL trial. The manuscript ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback